Israel Englander Akouos, Inc. Transaction History

Millennium Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$2.6 - $5.16 $586,029 - $1.16 Million	-225,396 Reduced 24.61%	690,452 $4.67 Million
Q2 2022 Aug 15, 2022	BUY	$2.46 - $5.2 $1.18 Million - $2.49 Million	478,209 Added 109.27%	915,848 $4.3 Million
Q1 2022 May 16, 2022	BUY	$4.16 - $9.08 $900,506 - $1.97 Million	216,468 Added 97.87%	437,639 $2.08 Million
Q4 2021 Feb 14, 2022	BUY	$7.65 - $11.38 $63,648 - $94,681	8,320 Added 3.91%	221,171 $1.88 Million
Q3 2021 Nov 15, 2021	SELL	$9.93 - $13.59 $254,754 - $348,651	-25,655 Reduced 10.76%	212,851 $2.47 Million
Q2 2021 Aug 16, 2021	BUY	$11.87 - $15.96 $816,893 - $1.1 Million	68,820 Added 40.56%	238,506 $2.99 Million
Q1 2021 May 17, 2021	SELL	$13.87 - $21.04 $1.14 Million - $1.73 Million	-82,017 Reduced 32.58%	169,686 $2.35 Million
Q4 2020 Feb 16, 2021	BUY	$17.03 - $22.45 $1.17 Million - $1.54 Million	68,716 Added 37.55%	251,703 $4.99 Million
Q3 2020 Nov 16, 2020	SELL	$19.3 - $26.92 $2.02 Million - $2.81 Million	-104,455 Reduced 36.34%	182,987 $4.19 Million
Q2 2020 Aug 14, 2020	BUY	$22.0 - $22.5 $6.32 Million - $6.47 Million	287,442 New	287,442 $6.47 Million

Ticker AKUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,929,000
Description
Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therap...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.